Drug Profile
Bruton's tyrosine kinase inhibitor - Bristol-Myers Squibb
Alternative Names: Btk inhibitor - BMS; BTK-MaxLatest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Amides; Purines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 27 Dec 2022 Discontinued - Phase-I for Immunological disorders in USA (PO)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Immunological-disorders in USA (PO)
- 11 Apr 2018 Phase I development in Immunological disorders is ongoing (Bristol-Myers Squibb pipeline, April 2018)